Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili, its biosimilar to Eylea. The agreement allows Biocon ...

“This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality aflibercept biosimilar to patients and healthcare providers in the U.S.,” said Shreehas ...

Biocon rose 3.10% to Rs 326.35 after the company's subsidiary Biocon Biologics signed a settlement and license agreement with Regeneron, paving the way to commercialize Yesafili, a biosimilar to EYLEA ...

Maskell + Josephson Optometrists in Regent Road, is "one of only a handful of practices in the UK" (as per a spokesperson) to be using the Valeda Light Delivery System, a device for treating dry ...

Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the United States Court of Appeals for the Federal Circuit (USCAFC) of patent US11084865 ('865 patent) ...

Assessing blood vessels at the back of the eye may one day become an accessible and cost-effective way to determine dementia risk. | Neuroscience ...

Surgeons from a specialist UK eye hospital have helped save the sight of more than 20 Bangladeshi students who were wounded ...

Iridex Corporation (Nasdaq:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal ...

Most patients in the United States who present to hospital emergency departments with acute central retinal artery occlusion do not undergo stroke workup imaging.

Need new glasses? Online eye exams and vision tests offer a convenient way to get a glasses prescription. Doctors explain ...

What causes schizophrenia? This severe mental illness, which affects more than 20 million people worldwide and is characterized by recurrent hallucinations and delusions, often begins to emerge in the ...

These findings significantly expand our fundamental scientific understanding of age-related retinal diseases while offering potential new biomarkers ...